<DOC>
	<DOCNO>NCT00858455</DOCNO>
	<brief_summary>The purpose study effect Maalox® One A Day® pharmacokinetics GSK1349572 , also compare safety GSK1349572 administer alone administer Maalox® One A Day® . There four dosing period study , period require 4 night stay . A follow-up visit also require approximately 7 day last dose administration . Starting first period follow-up , take 1 month . Screening visit require complete within 30 day prior first dose . MAALOX® register trademark Novartic Consumer Health , LLC . ONE A DAY® register trademark Bayer Healthcare LLC .</brief_summary>
	<brief_title>A Study Evaluate Effect Antacid Multivitamin Mineral Tablet Study Drug GSK1349572</brief_title>
	<detailed_description />
	<mesh_term>Aluminum hydroxide , magnesium hydroxide , drug combination</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male female 18 65 year age . A female subject eligible participate nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include female : Is premenopausal documented bilateral tubal ligation , bilateral oophorectomy ( removal ovary ) hysterectomy , Is postmenopausal defined 12 month spontaneous amenorrhea . A follicle stimulate hormone ( FSH ) level perform confirm postmenopausal status . For study , FSH level &gt; 40 mlU/ml confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt , HRT discontinue 2 week subject rescreened , HRT suppress FSH . Male subject must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication 14 day last dose study medication . Body weight ≥ 50 kg men ≥ 45 kg woman body mass index ( BMI ) within range 18.531.0 kg/m2 ( inclusive ) . AST , ALT , alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . One repeat measurement confirm eligibility allow . Capable give write informed consent , include compliance requirement restriction list consent form . A subject eligible inclusion study follow criterion apply : The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . History sensitivity study medication , component thereof , history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . If heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . One drink equivalent ( 12 g alcohol ) = 5 ounce ( 150 ml ) wine 12 ounce ( 360 ml ) beer 1.5 ounce ( 45 ml ) 80 proof distil spirit . Consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . Pregnant female determine positive serum urine human chorionic gonadotrophin ( hCG ) test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy exclude . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive Hepatitis B surface antigen positive Hepatitis C antibody result . A positive test HIV antibody . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject . A single repeat determine eligibility allow . Exclusion criterion screen ECG specify protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Drug interation , Pharmacokinetics</keyword>
</DOC>